Serum levels of miR-21, miR-23a, miR-142-5p, and miR-126 in chronic failure with reduced ejection fraction: a case-control study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F25%3AE0111717" target="_blank" >RIV/00843989:_____/25:E0111717 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/25:A2603DAB

Výsledek na webu

<a href="https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2025.1529451/full" target="_blank" >https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2025.1529451/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fcvm.2025.1529451" target="_blank" >10.3389/fcvm.2025.1529451</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Serum levels of miR-21, miR-23a, miR-142-5p, and miR-126 in chronic failure with reduced ejection fraction: a case-control study

Popis výsledku v původním jazyce

Background: MicroRNAs (miRNAs) are small non-coding RNA molecules that function as gene regulators in physiological processes, including proliferation, differentiation, and apoptosis. Various microRNAs have been linked to pathophysiological events associated with heart disease. In this case-control study, we investigated the levels of human miR-21, miR-23a, miR-142-5p, and miR-126 among heart failure patients with reduced ejection fraction (HFrEF), compared to healthy control participants. Methods: We prospectively enrolled clinically stable patients with heart failure (HF) and left ventricle ejection fraction (LVEF) ? 40%, and healthy individuals. MicroRNAs were analyzed from venous blood, using a microRNA enzymatic immunoassay (miREIA) method. Plasma miRNA levels were compared between HFrEF patients and healthy individuals, using non-parametric tests. Results: We enrolled 73 patients with HFrEF (86% males, mean age: 66.3 ± 10.7 years) and 99 healthy subjects (36% males, mean age: 44.7 ± 15.9 years). All four assayed miRNAs exhibited significantly higher median levels in heart failure patients compared to healthy controls: miR-21p, 243 pmol·l-1 vs. 14 pmol·l-1; miR-23a-3p, 705 pmol·l-1 vs. 119 pmol·l-1; miR-142-5p, 1,695 pmol·l-1 vs. 146 pmol·l-1; and miR-126-3p, 528 pmol·l-1 vs.21 pmol·l-1 (P ? 0.001 for all). The analyzed miRNA levels did not differ according to age, weight, height, or body mass index. No miRNA levels correlated with NTproBNP levels. Conclusion: Our findings revealed that the levels of miR-21-5p, miR-23a-3p, miR-142-5p,and miR-126-3p were significantly higher among HFrEF patients compared to healthy controls. Further exploration of these miRNAs may lead to new diagnostic, prognostic, and therapeutic options for HF patients.

Název v anglickém jazyce

Serum levels of miR-21, miR-23a, miR-142-5p, and miR-126 in chronic failure with reduced ejection fraction: a case-control study

Popis výsledku anglicky

Background: MicroRNAs (miRNAs) are small non-coding RNA molecules that function as gene regulators in physiological processes, including proliferation, differentiation, and apoptosis. Various microRNAs have been linked to pathophysiological events associated with heart disease. In this case-control study, we investigated the levels of human miR-21, miR-23a, miR-142-5p, and miR-126 among heart failure patients with reduced ejection fraction (HFrEF), compared to healthy control participants. Methods: We prospectively enrolled clinically stable patients with heart failure (HF) and left ventricle ejection fraction (LVEF) ? 40%, and healthy individuals. MicroRNAs were analyzed from venous blood, using a microRNA enzymatic immunoassay (miREIA) method. Plasma miRNA levels were compared between HFrEF patients and healthy individuals, using non-parametric tests. Results: We enrolled 73 patients with HFrEF (86% males, mean age: 66.3 ± 10.7 years) and 99 healthy subjects (36% males, mean age: 44.7 ± 15.9 years). All four assayed miRNAs exhibited significantly higher median levels in heart failure patients compared to healthy controls: miR-21p, 243 pmol·l-1 vs. 14 pmol·l-1; miR-23a-3p, 705 pmol·l-1 vs. 119 pmol·l-1; miR-142-5p, 1,695 pmol·l-1 vs. 146 pmol·l-1; and miR-126-3p, 528 pmol·l-1 vs.21 pmol·l-1 (P ? 0.001 for all). The analyzed miRNA levels did not differ according to age, weight, height, or body mass index. No miRNA levels correlated with NTproBNP levels. Conclusion: Our findings revealed that the levels of miR-21-5p, miR-23a-3p, miR-142-5p,and miR-126-3p were significantly higher among HFrEF patients compared to healthy controls. Further exploration of these miRNAs may lead to new diagnostic, prognostic, and therapeutic options for HF patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Frontiers in cardiovascular medicine

ISSN

2297-055X

e-ISSN

2297-055X

Svazek periodika

12

Číslo periodika v rámci svazku

article 1529451

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

9

Strana od-do

1-9

Kód UT WoS článku

001497954300001

EID výsledku v databázi Scopus

2-s2.0-105006920125